Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People’s Republic of China.
Metrics to compare | 603087 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship603087PeersSector | |
---|---|---|---|---|
P/E Ratio | 40.7x | 37.7x | −0.5x | |
PEG Ratio | 0.52 | −1.15 | 0.00 | |
Price/Book | 3.4x | 2.1x | 2.6x | |
Price / LTM Sales | 9.9x | 7.4x | 3.3x | |
Upside (Analyst Target) | 5.6% | 0.3% | 40.1% | |
Fair Value Upside | Unlock | 8.2% | 5.1% | Unlock |